Monte Rosa Therapeutics(US:GLUE) Globenewswire·2025-07-03 18:15Core Insights - Monte Rosa Therapeutics has published significant findings in Science, revealing how its AI/ML technology expands the targetable protein space for molecular glue degraders, potentially addressing previously undruggable therapeutic targets [1][2]. Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, including oncology and autoimmune conditions [3]. - The company utilizes its proprietary QuEEN™ discovery engine, which integrates AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with unprecedented selectivity [3]. Research and Development - The recent research highlights the ability of Monte Rosa's QuEEN discovery engine to identify over 100 new protein targets that are amenable to degradation, many of which are currently considered inaccessible to small molecule binding [2]. - The findings significantly broaden the therapeutic reach of Monte Rosa's pipeline, particularly in immunology, inflammation, and oncology, where the company is advancing clinical programs [2]. Strategic Collaborations - Monte Rosa has established a global license agreement with Novartis to develop VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover MGDs targeting cancer and neurological diseases previously deemed impossible to drug [3].